Jefferies downgraded uniQure (NASDAQ:QURE) from Buy to Hold in a report released today.
- Updated: November 27, 2016
Jefferies has downgraded uniQure (NASDAQ:QURE) from Buy to Hold in a report released on Tuesday November 22, 2016.
Previously on 11/17/2016, Zacks Investment Research reported on uniQure (NASDAQ:QURE) increased the target price from $0.00 to $8.00. At the time, this indicated a possible upside of 0.14%.
Just yesterday uniQure (NASDAQ:QURE) traded 2.39% higher at $7.13. uniQure’s 50-day moving average is $7.17 and its 200-day moving average is $8.54. The last closing price is down -19.81% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 58,487 shares of QURE traded hands, down from an average trading volume of 226,691
Recent Performance Chart
uniQure has 52 week low of $6.41 and a 52 week high of $22.00 and has a market capitalization of $0.
Brief Synopsis On uniQure (NASDAQ:QURE)
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson's Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington's disease, in which the Company has demonstrated preclinical proof of concept.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.